文献速递复苏、休克与脓毒症重症综合管理与镇静镇痛

血管舒张性低血压中较低与较高血管升压药暴露的比较:系统评价与Meta分析

Lower Versus Higher Exposure to Vasopressor Therapy in Vasodilatory Hypotension: A Systematic Review With Meta-Analysis.
PubMed 文献 · Crit Care Med · 2022-11-18
一句话结论在因血管舒张性低血压启动血管升压药的成人ICU患者中,中等确定性证据显示较低升压药暴露可能降低90天死亡率(RR 0.94;95%CI 0.87-1.02),但置信区间跨1、未达统计学显著。

该系统评价与Meta分析检索Ovid Medline、Embase和Cochrane Central Register of Controlled Trials自建库至2021年10月15日的文献,纳入成人ICU血管舒张性低血压患者中比较较低与较高血管升压药暴露的随机对照试验。共检索到3403条记录,审阅68篇全文,最终纳入3项研究。主要终点90天全因死亡率:较低暴露可能降低死亡率(RR 0.94;95%CI 0.87-1.02),为中等确定性证据,因不精确性降级;未发现可信的亚组效应。较低升压药暴露还可能降低室上性心律失常风险(OR 0.55;95%CI 0.36-0.86;低确定性)。作者结论认为需要更多试验数据达到最佳信息量,以检出该策略10%的相对死亡率下降。

要点

  • 在成人ICU血管舒张性低血压患者中,较低血管升压药暴露可能降低90天全因死亡率(RR 0.94;95%CI 0.87-1.02),为中等确定性证据,因不精确性降级。
  • 较低血管升压药暴露可能降低室上性心律失常风险(OR 0.55;95%CI 0.36-0.86),证据确定性低。
  • 预设的7个亚组中未发现可信的亚组效应。
  • 作者结论认为需要更多试验数据以达到最佳信息量,检出该策略10%的相对死亡率下降。

适用人群与场景

  • 成人ICU患者,因血管舒张性低血压而启动血管升压药治疗。

研究设计与关键结果

  • 研究类型:系统评价与Meta分析,纳入3项随机对照试验;检索Ovid Medline、Embase和Cochrane Central Register of Controlled Trials自建库至2021年10月15日,共检索到3403条记录,审阅68篇全文,最终纳入3项合格研究。
  • 主要终点90天全因死亡率:较低血管升压药暴露可能降低死亡率(RR 0.94;95%CI 0.87-1.02),为中等确定性证据,因不精确性降级;未发现可信的亚组效应。
  • 次要终点室上性心律失常:较低血管升压药暴露可能降低其风险(OR 0.55;95%CI 0.36-0.86;低确定性)。

证据类型、等级与局限

  • 证据类型:系统评价与Meta分析,纳入3项随机对照试验;采用GRADE评估证据确定性,主要终点为中等确定性证据(因不精确性降级),室上性心律失常为低确定性证据。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 对因血管舒张性低血压启动血管升压药的成人ICU患者,中等确定性证据显示较低升压药暴露可能降低90天死亡率(RR 0.94;95%CI 0.87-1.02),但置信区间跨1、未达统计学显著。
  • 较低升压药暴露可能降低室上性心律失常风险(OR 0.55;95%CI 0.36-0.86;低确定性)。
  • 作者认为需要更多试验数据以达到最佳信息量,检出该策略10%的相对死亡率下降。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

OBJECTIVES: Balancing the risks of hypotension and vasopressor-associated adverse effects is a daily challenge in ICUs. We conducted a systematic review with meta-analysis to examine the effect of lower versus higher exposure to vasopressor therapy on mortality among adult ICU patients with vasodilatory hypotension.

DATA SOURCES: We searched Ovid Medline, Embase, and the Cochrane Central Register of Controlled Trials for studies published from inception to October 15, 2021.

STUDY SELECTION: We included randomized controlled trials of lower versus higher exposure to vasopressor therapy in adult ICU patients with vasodilatory hypotension without language or publication status limits.

DATA EXTRACTION: The primary outcome was 90-day all-cause mortality, with seven prespecified subgroups. Secondary outcomes included shorter- and longer-term mortality, use of life-sustaining therapies, vasopressor-related complications, neurologic outcome, and quality of life at longest reported follow-up. We conducted random-effects meta-analyses to calculate summary effect measures across individual studies (risk ratio [RR] for dichotomous variables, mean difference for continuous variables, both with 95% CIs). The certainty of the evidence was assessed using Grading of Recommendations, Assessment, Development, and Evaluation. We registered this review on the International Prospective Register of Systematic Reviews (CRD42021224434).

DATA SYNTHESIS: Of 3,403 records retrieved, 68 full-text articles were reviewed and three eligible studies included. Lower exposure to vasopressors probably lowers 90-day mortality but this is based on moderate-certainty evidence, lowered for imprecision (RR, 0.94; 95% CI, 0.87-1.02). There was no credible subgroup effect. Lower vasopressor exposure may also decrease the risk of supraventricular arrhythmia (odds ratio, 0.55; 95% CI, 0.36-0.86; low certainty).

CONCLUSIONS: In patients with vasodilatory hypotension who are started on vasopressors, moderate-certainty evidence from three randomized trials showed that lower vasopressor exposure probably lowers mortality. However, additional trial data are needed to reach an optimal information size to detect a clinically important 10% relative reduction in mortality with this approach.

来源:Crit Care Med,查看原文。版权归原作者所有。

参考来源

  1. Richards-Belle A, Hylands M, Muttalib F, et al. Lower Versus Higher Exposure to Vasopressor Therapy in Vasodilatory Hypotension: A Systematic Review With Meta-Analysis. Crit Care Med. 2022. PMID: 36398968. doi:10.1097/CCM.0000000000005736

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。